FrancophonIA/ELRC3.0 huggingface dataset:
English: Emtricitabine/Tenofovir disoproxil Krka is indicated in combination with safer sex practices for preexposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1).
Danish: Emtricitabine/Tenofovir disoproxil Krka er i kombination med god praksis for sikker sex indiceret som profylakse før eksponering for at mindske risikoen for seksuelt erhvervet HIV 1-infektion hos meget udsatte voksne (se pkt.
English: Individuals with renal impairment: Since tenofovir disoproxil can cause renal toxicity, close monitoring of renal function is recommended in any adults with renal impairment receiving Emtricitabine/Tenofovir disoproxil Krka (see sections 4.2, 4.4 and 5.2).
Danish: Personer med nedsat nyrefunktion: Da tenofovirdisoproxil kan forårsage nefrotoksicitet, anbefales tæt monitorering af nyrefunktionen hos alle voksne med nedsat nyrefunktion, som får Emtricitabine/Tenofovir disoproxil Krka (se pkt.
English: What Emtricitabine/Tenofovir disoproxil Krka looks like and contents of the pack Emtricitabine/Tenofovir disoproxil Krka film coated tablets (tablets) are blue, oval, biconvex tablets, of dimensions 20 mm x 10 mm.
Danish: Emtricitabine/Tenofovir disoproxil Krka filmovertrukne tabletter (tabletter) er blå, ovale, bikonvekse tabletter, der måler 20 mm x 10 mm.
English: Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide or other cytidine analogues, such as lamivudine (see section 4.4).
Danish: Emtricitabine/Tenofovir disoproxil Krka bør ikke administreres samtidig med andre lægemidler, som indholder emtricitabin, tenofovirdisoproxil, tenofoviralafenamid eller andre cytidinanaloger, såsom lamivudin (se pkt.
English: If serum phosphate is confirmed to be < 3.0 mg/dl (0.96 mmol/l) in any paediatric patient receiving Emtricitabine/Tenofovir disoproxil Krka, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Danish: Hvis serumphosphat bekræftes at være < 3,0 mg/dl (0,96 mmol/l) hos en pædiatrisk patient, der får Emtricitabine/Tenofovir disoproxil Krka, skal nyrefunktionen revurderes inden for en uge, herunder måling af blodglucose, blodkalium og uringlucose (se pkt.
English: Recommendation concerning coadministration with Emtricitabine/Tenofovir disoproxil Krka (emtricitabine 200 mg, tenofovir disoproxil 245 mg)
Danish: samtidig administration af Emtricitabine/Tenofovir disoproxil Krka (emtricitabin 200 mg, tenofovirdisoproxil 245 mg)
English: Didanosine: The co-administration of Emtricitabine/Tenofovir disoproxil Krka and didanosine is not recommended (see section 4.4 and Table 2).
Danish: Didanosin: Samtidig administration af Emtricitabine/Tenofovir disoproxil Krka og didanosin anbefales ikke (se pkt.
English: The safety of tenofovir disoproxil when co-administered with ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir and a pharmacokinetic enhancer has not been established.
Danish: Sikkerheden af tenofovirdisoproxil ved administration sammen med ledipasvir/sofosbuvir sofosbuvir/velpatasvir eller sofosvubir/velpatasvir/voxilaprevir og en farmakokinetisk forstærker er ikke klarlagt.
English: HIV-Positive Subjects HIV-Negative Matched Control Subjects 63 (44%)
Danish: HIV-Positive Forsøgspersoner HIV-Negative Matchede Kontrolpersoner
English: If vomiting occurs more than 1 hour after taking Emtricitabine/Tenofovir disoproxil Krka a second dose should not be taken.
Danish: Hvis patienten kaster op mere end 1 time efter at have taget Emtricitabine/Tenofovir disoproxil Krka, må patienten ikke tage en ny dosis.
English: The combination should be used with caution with frequent renal monitoring, if other alternatives are not available
Danish: Hvis der ikke er andre alternativer, skal kombinationen anvendes med forsigtighed og hyppig monitorering af
English: If renal abnormalities are detected or suspected then consultation with a nephrologist should be obtained to consider interruption of Emtricitabine/Tenofovir disoproxil Krka treatment - That Emtricitabine/Tenofovir disoproxil Krka may cause a reduction in BMD and the effects of Emtricitabine/Tenofovir disoproxil Krka associated changes in BMD on long term bone health and future fracture risk are currently unknown in paediatric patients - That if bone abnormalities are detected or suspected then consultation with an endocrinologist and/or nephrologist should be obtained
Danish: - At Emtricitabine/Tenofovir disoproxil Krka kan give anledning til et fald i BMD, og at indvirkningen på knoglesundheden på langt sigt og på den fremtidige frakturrisiko af de ændringer i BMD, der forbindes med Emtricitabine/Tenofovir disoproxil Krka, p.t. ikke er kendt hos pædiatriske patienter - At der bør søges råd hos en endokrinolog og/eller en nefrolog, hvis knogleabnormiteter mistænkes eller påvises hos pædiatriske patienter
English: If serum phosphate is < 1.5 mg/dL (0.48 mmol/L) or creatinine clearance is decreased to < 60 mL/min in any individual receiving Emtricitabine/Tenofovir disoproxil Krka for pre-exposure prophylaxis, renal function should be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Danish: Hvis serumphosphat er < 1,5 mg/dl (0,48 mmol/L) eller kreatininclearance reduceret til < 60 ml/min hos en person, der får Emtricitabine/Tenofovir disoproxil Krka som profylakse før eksponering, skal nyrefunktionen revurderes inden for en uge, herunder måling af blodglucose, blodkalium og uringlucose (se pkt.
English: Placebo Tenofovir disoproxil 245 mg +Emtricitabine/tenofovir disoproxil
Danish: Tenofovirdisoproxil 245 mg + Emtricitabine/tenofovirdisoproxi
English: Co-administration of Emtricitabine/Tenofovir disoproxil Krka and didanosine is not recommended (see section 4.4).
Danish: Samtidig administration af Emtricitabine/Tenofovir disoproxil Krka og didanosin kan ikke anbefales (se pkt.
English: The following may be signs of lactic acidosis: deep rapid breathing drowsiness feeling sick (nausea), being sick (vomiting) stomach pain
Danish: Følgende kan være tegn på laktatacidose: dyb, hurtig vejrtrækning døsighed kvalme, opkastning mavesmerter → Hvis De tror, De har laktatacidose, skal De straks søge læge.
English: Lactic acidosis (see Possible serious side effects) fatty liver yellow skin or eyes, itching, or pain in the abdomen (tummy) caused by inflammation of the liver inflammation of the kidney, passing a lot of urine and feeling thirsty, kidney failure, damage to kidney tubule cells softening of the bones (with bone pain and sometimes resulting in fractures) back pain caused by kidney problems
Danish: Sjældne bivirkninger (kan opstå hos op til 1 ud af 1.000 personer) laktatacidose (se Alvorlige bivirkninger) fedtlever gulfarvning af hud eller øjne, kløe eller mavesmerter på grund af leverbetændelse inflammation i nyrerne, udskillelse af store mængder urin, tørst, nyresvigt, skade på tubulære celler i nyrerne blødgøring af knoglerne (med knoglesmerter og af og til med knoglebrud til følge) rygsmerter på grund af nyreproblemer
English: Darunavir/Ritonavir/Emtricitabine Interaction not studied.
Danish: Darunavir/Ritonavir/Emtricitabin Interaktion er ikke undersøgt.
English: Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg film-coated tablets Emtricitabine/Tenofovir disoproxil
Danish: Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg filmovertrukne tabletter Emtricitabin/tenofovirdisoproxil (Emtricitabinum/Tenofovirum disoproxilum)
English: AUC: ↑ 65% (↑ 59 to ↑ 71) Cmax: ↑ 61% (↑ 51 to ↑ 72) Cmin: ↑ 115% (↑ 105 to ↑ 126)
Danish: AUC: ↑ 65% (↑ 59 til ↑ 71) Cmax: ↑ 61% (↑ 51 til ↑ 72) Cmin: ↑ 115% (↑ 105 til ↑ 126)
English: Adherence Substudy Adherence Substudy Participants
Danish: Deltagere i Adhærensdelstudiet
English: NARCOTIC ANALGESICS Methadone/Tenofovir disoproxil
Danish: NARKOTISKE ANALGETIKA Methadon/Tenofovirdisoproxil
English: AUC: ↑ 142% (↑ 123 to ↑ 164) Cmax: ↑ 55% (↑ 41 to ↑ 71) Cmin: ↑ 301% (↑ 257 to ↑ 350)
Danish: AUC: ↑ 142% (↑ 123 til ↑ 164) Cmax: ↑ 55% (↑ 41 til ↑ 71) Cmin: ↑ 301% (↑ 257 til ↑ 350)
English: FTC/tenofovir disoproxil Group
Danish: FTC/tenofovirdisoproxil-gruppe
English: HIV-1 RNA < 50 copies/mL (TLOVR)
Danish: Hiv 1-rna < 50 kopier /ml (TLOVR) p-værdi % forskel (95%CI)
English: It is important not to miss a dose of Emtricitabine/Tenofovir disoproxil Krka.
Danish: Det er vigtigt, at De husker at tage alle doser Emtricitabine/Tenofovir disoproxil Krka.
English: AUC: ↓ 25% (↓ 42 to ↓ 3) Cmax: ↓ 28% (↓ 50 to ↑ 5) Cmin: ↓ 26% (↓ 46 to ↑ 10) Tenofovir:
Danish: AUC: ↓ 25% (↓ 42 til ↓ 3) Cmax: ↓ 28% (↓ 50 til ↑ 5) Cmin: ↓ 26% (↓ 46 til ↑ 10)
English: Hepatic impairment: No dose adjustment is required in patients with hepatic impairment (see sections 4.4 and 5.2).
Danish: Nedsat leverfunktion: Dosisjustering er ikke nødvendig hos patienter med nedsat leverfunktion (se pkt.
English: Placebo Emtricitabine/tenofovir disoproxil
Danish: Placebo Emtricitabine/tenofovirdisoproxil
English: anaemia
Danish: anæmi
English: While taking Emtricitabine/Tenofovir disoproxil Krka to treat HIV or to reduce the risk of getting HIV:
Danish: Hvis De tager Emtricitabine/Tenofovir disoproxil Krka for at behandle HIV eller reducere risikoen for at få HIV:
English: Adefovir dipivoxil and Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly (see section 4.4).
Danish: Adefovirdipivoxil og Emtricitabine/Tenofovir disoproxil Krka må ikke administreres samtidigt (se pkt.
English: See Table
Danish: Se Tabel 1.
English: Emtricitabine/Tenofovir disoproxil Krka is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents (see sections 4.2, 4.4 and 5.1).
Danish: Emtricitabine/Tenofovir disoproxil Krka er også indiceret til behandling af HIV 1-inficerede med NRTI-resistens eller -toksicitet, der udelukker brug af førstevalgspræparater (se pkt.
English: Emtricitabine+ tenofovir disoproxil +efavirenz
Danish: Emtricitabin+ Tenofovirdisopro xil+efavirenz
English: The recommended dose of Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV is:
Danish: Den anbefalede dosis af Emtricitabine/Tenofovir disoproxil Krka til at nedsætte risikoen for at få HIV er:
English: Detection Versus No Detection of Tenofovir
Danish: Risikoestimat for HIV 1Beskyttelse: Detektering af vs. ingen detektering af Tenofovir
English: Administration every 48 hours is recommended based on modelling of single-dose pharmacokinetic data for emtricitabine and tenofovir disoproxil in non-HIV infected subjects with varying degrees of renal impairment (see section
Danish: Ud fra modellering af farmakokinetiske data for enkeltdosis af emtricitabin og tenofovirdisoproxil hos ikke-hiv-inficerede forsøgspersoner med varierende grader af nedsat nyrefunktion anbefales det at administrere hver 48. time (se pkt.
English: The increased exposure of tenofovir could potentiate tenofovir associated adverse events, including renal disorders.
Danish: Den forøgede tenofovir-eksponering kan øge risikoen for bivirkninger af tenofovir, herunder renale lidelser.
English: Then mix the powder with about 100 mL (half a glass) of water, orange juice or grape juice, and drink immediately.
Danish: Hvis De har problemer med at synke, kan De knuse tabletten med spidsen af en ske og opløse den i ca. 100 mL (et halvt glas) vand, appelsinjuice eller druesaft.
English: HIV-1 infection: The most frequently reported adverse reactions considered possibly or probably related to emtricitabine and/or tenofovir disoproxil were nausea (12%) and diarrhoea (7%) in an openlabel randomised clinical study in adults (GS-01-934, see section 5.1).
Danish: 5.1) var de hyppigst indberettede bivirkninger, som blev anset for at have en mulig eller sandsynlig forbindelse til emtricitabin og/eller tenofovirdisoproxil, kvalme (12 %) og diarré (7 %).
English: HIV-1 RNA < 400 copies/mL (TLOVR)
Danish: Hiv 1-rna < 400 kopier/ml (TLOVR) p-værdi % forskel (95%CI)
English: Manufacturers
Danish: PRODUKTRESUMÉ
English: Concomitant administration of sofosbuvir/velpatasvir and efavirenz is
Danish: Sofosbuvir/velpatasvir/
English: Difference (95%CI) 32 (9 to 55)
Danish: 32 (9 til 55)
English: AUC: ↓ 34% (↓ 41 to ↓ 25) Cmax: ↓ 34% (↓ 41 to ↑ 25) Cmin: ↓ 34% (↓ 43 to ↑ 24) Sofosbuvir:
Danish: AUC: ↓ 34% (↓ 41 til ↓ 25) Cmax: ↓ 34% (↓ 41 til ↑ 25) Cmin: ↓ 34% (↓ 43 til ↑ 24)
English: AUC: ↓ 27% (↓ 35 to ↓ 18) Cmax: ↓ 37% (↓ 48 to ↓ 25) GS-331007
Danish: AUC: ↓ 27% (↓ 35 til ↓ 18) Cmax: ↓ 37% (↓ 48 til ↓ 25)
English: The mean (%CV) tenofovir drug exposure increased from 2,185 (12%) ng•h/mL in subjects with normal renal function, to 3,064 (30%) ng•h/mL, 6,009 (42%) ng•h/mL and 15,985 (45%) ng•h/mL, in subjects with mild, moderate and severe renal impairment, respectively.
Danish: Den gennemsnitlige (% variationskoefficient) tenofovireksponering steg fra 2.185 (12%) ng•t/mL hos forsøgspersoner med normal nyrefunktion til 3.064 (30%) ng•t/mL, 6.009 (42%) ng•t/mL og
English: - Reminder of the key safety information regarding the use of Emtricitabine/Tenofovir disoproxil Krka for PrEP in adults and adolescents - Reminder of factors to help identify individuals at high risk of acquiring HIV 1 - Reminder on the risk of development of HIV 1 drug resistance in undiagnosed HIV 1
Danish: - Påmindelse om faktorer til hjælp til at identificere personer med høj risiko for at få HIV 1 - Påmindelse om risikoen for at udvikle resistens over for HIV 1-medicin hos ikke diagnosticerede HIV 1-inficerede personer - Give sikkerhedsoplysninger om adhærens, HIV-testning samt nyre-, knogle- og HBV-status.
English: Consideration should be given to interrupting use of Emtricitabine/Tenofovir disoproxil Krka in individuals with creatinine clearance decreased to < 60 mL/min or decreases in serum phosphate to < 1.0 mg/dL (0.32 mmol/L).
Danish: Det bør overvejes at afbryde brugen af Emtricitabine/Tenofovir disoproxil Krka hos personer, hvor kreatininclearance er faldet til < 60 ml/min eller serumphosphat til < 1,0 mg/dl (0,32 mmol/L), ligesom det bør overvejes at afbryde behandlingen i tilfælde af progredierende fald i nyrefunktionen, når ingen anden årsag er blevet identificeret.
English: IMMUNOSUPPRESSANTS Tacrolimus/Tenofovir disoproxil /Emtricitabine
Danish: IMMUNSUPPRESSIVA Tacrolimus/Tenofovirdisoproxil/Emt ricitabin
English: Before taking Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV:
Danish: Inden De tager Emtricitabine/Tenofovir disoproxil Krka for at nedsætte risikoen for at få HIV:
English: Lopinavir/Ritonavir/Tenofovir disoproxil (400 mg b.i.d./100 mg b.i.d/245 mg q.d.)
Danish: Tenofovirdisoproxilt (400 mg b.i.d./100 mg b.i.d./245 mg q.d.)
English: Emtricitabine/tenofovir disoproxil
Danish: Emtricitabinum/Tenofovirum disoproxilum
English: AUC: ↑ 96% (↑ 74 to ↑ 121) Cmax: ↑ 68% (↑ 54 to ↑ 84) Cmin: ↑ 118% (↑ 91 to ↑ 150) Sofosbuvir:
Danish: AUC: ↑ 96% (↑ 74 til ↑ 121) Cmax: ↑ 68% (↑ 54 til ↑ 84) Cmin: ↑ 118% (↑ 91 til ↑ 150)
English: Tenofovir disoproxil Group
Danish: Tenofovirdisoproxil-gruppe
English: The safety of tenofovir disoproxil when used with sofosbuvir/velpatasvir/voxilaprevir and a pharmacokinetic enhancer (e.g. ritonavir or cobicistat) has not been established.
Danish: Sikkerheden af tenofovirdisoproxil sammen med sofosbuvir/velpatasvir/voxila previr og en farmakokinetisk booster (f.eks. ritonavir eller cobicistat) er ikke klarlagt.
English: Seven patients had estimated glomerular filtration rate (GFR) values between 70 and 90 mL/min/1.73 m2.
Danish: 7 patienter havde en estimeret glomerulær filtrationshastighed (GFR) mellem 70 og 90 ml/min/1,73 m2. Under behandlingen oplevede 3 af disse patienter et klinisk betydningsfuldt fald i estimeret GFR, som blev forbedret efter seponering af tenofovirdisoproxil.
English: Cmax: ↑ 34%
Danish: Cmin: ↓ 34%
English: Cmin: ↑ 45% (↑ 27 to ↑ 64) Emtricitabine:
Danish: Cmin: ↑ 45% (↑ 27 til ↑ 64)
English: If serum phosphate is < 1.5 mg/dL (0.48 mmol/L) or creatinine clearance is decreased to < 50 mL/min in any patient receiving Emtricitabine/Tenofovir disoproxil Krka, renal function should be reevaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy).
Danish: Håndtering af nedsat nyrefunktion hos HIV 1-inficerede patienter Hvis serumphosphat er < 1,5 mg/dl (0,48 mmol/L), eller kreatininclearance er reduceret til < 50 ml/min hos patienter, der får Emtricitabine/Tenofovir disoproxil Krka, bør nyrefunktionen revurderes inden for en uge, herunder måling af blodglucose, blodkalium og uringlucose (se pkt.
English: Do not miss any doses of Emtricitabine/Tenofovir disoproxil Krka, or stop taking it.
Danish: Lad være med at springe Emtricitabine/Tenofovir disoproxil Krka -doser over eller holde op med at tage Emtricitabine/Tenofovir disoproxil Krka.
English: In HIV-1 infected patients with renal risk factors, the co-administration of tenofovir disoproxil with a boosted protease inhibitor should be carefully evaluated.
Danish: Samtidig behandling med tenofovirdisoproxil og en boosted proteasehæmmer skal evalueres omhyggeligt hos hiv 1inficerede patienter med renale risikofaktorer.
English: Cmax: ↓ 19% (↓ 40 to ↑ 10) GS-331007
Danish: Cmax: ↓ 19% (↓ 40 til ↑ 10)
English: Rare side effects
Danish: bivirkninger.
English: Just taking Emtricitabine/Tenofovir disoproxil Krka may not stop you getting HIV.
Danish: Det er ikke nødvendigvis nok at tage Emtricitabine/Tenofovir disoproxil Krka for at undgå at få HIV.
English: The time to onset of protection after commencing Emtricitabine/Tenofovir disoproxil Krka is unknown.
Danish: Det vides ikke, hvor lang tid der går efter start af Emtricitabine/Tenofovir disoproxil Krkabehandling, før den beskyttende virkning opnås.
English: In study GS-US-104-0352, 97 treatment-experienced patients 2 to < 12 years of age with stable, virologic suppression on stavudine- or zidovudine-containing regimens were randomised to either replace stavudine or zidovudine with tenofovir disoproxil (n = 48) or continue on their original regimen (n = 49) for 48 weeks.
Danish: Disse patienter blev randomiseret til enten at erstatte stavudin eller zidovudin med tenofovirdisoproxil (n = 48) eller fortsætte med deres oprindelige regime (n = 49) i 48 uger.
English: Look out for any symptoms of infection or other symptoms such as: - muscle weakness - weakness beginning in the hands and feet and moving up towards the trunk of the body - palpitations, tremor or hyperactivity
Danish: muskelsvaghed svaghed, der begynder i hænder og fødder og bevæger sig op mod selve kroppen hjertebanken, rysten (tremor) eller hyperaktivitet → Hvis De ser disse eller andre symptomer på inflammation eller infektion, skal De straks søge læge.
English: (9.0%) discontinued study drug due to renal adverse events.
Danish: Otte af de 89 patienter (9,0 %) seponerede studiemedicinen på grund af nyrebivirkninger.
English: What Emtricitabine/Tenofovir disoproxil Krka is and what it is used for What you need to know before you take Emtricitabine/Tenofovir disoproxil Krka How to take Emtricitabine/Tenofovir disoproxil Krka Possible side effects
Danish: Det skal De vide, før De begynder at tage Emtricitabine/Tenofovir disoproxil Krka Sådan skal De tage Emtricitabine/Tenofovir disoproxil Krka Bivirkninger
English: Cmin: ↑ 48% (↑ 34 to ↑ 63) Emtricitabine:
Danish: Cmin: ↑ 48% (↑ 34 til ↑ 63)
English: Cmin: ↑ 63% (↑ 45 to ↑ 84) Ritonavir:
Danish: Cmin: ↑ 63% (↑ 45 til ↑ 84)
English: Sofosbuvir/Velpatasvir/ Voxilaprevir (400 mg/100 mg/ 100 mg+100 mg q.d.)
Danish: voxilaprevir (400 mg/100 mg/ 100 mg+100 mg q.d.)
English: Lamivudine and
Danish: Lamivudin:
English: Co-administration is not recommended because it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Danish: Samtidig administration af tenofovirdisoproxil og didanosin Samtidig administration anbefales ikke, da det resulterer i en stigning på 40-60% i den systemiske eksponering for didanosin, hvilket kan øge risikoen for didanosinrelaterede bivirkninger (se pkt.
English: Cmax: ↑ 79% (↑ 56 to ↑ 104) Cmin: ↑ 163% (↑ 137 to ↑ 197)
Danish: AUC: ↑ 98% (↑ 77 til ↑ 123) Cmax: ↑ 79% (↑ 56 til ↑ 104) Cmin: ↑ 163% (↑ 137 til ↑ 197)
English: Atazanavir/Ritonavir/Tenofovir disoproxil (300 mg q.d./100 mg q.d./245 mg q.d.)
Danish: Tenofovirdisoproxil (300 mg q.d./100 mg q.d./245 mg q.d.)
English: Didanosine/Tenofovir disoproxil
Danish: Didanosin/Tenofovirdisoproxil
English: Other medicines and Emtricitabine/Tenofovir disoproxil Krka
Danish: Brug af anden medicin sammen med Emtricitabine/Tenofovir disoproxil Krka
English: for blisters:
Danish: for blistere:
English: Emtricitabine/Tenofovir disoproxil Krka is used to treat Human Immunodeficiency Virus 1 (HIV-1) infection in adults.
Danish: Emtricitabine/Tenofovir disoproxil Krka for at reducere risikoen for at få infektion forårsaget af humant immundefektvirus (HIV-infektion)” - PrEP-huskekort
English: Adefovir dipivoxil: AUC: ↓ 11% (↓ 14 to ↓ 7) Cmax: ↓ 7% (↓ 13 to ↓ 0) Cmin: NC
Danish: AUC: ↓ 11% (↓ 14 til ↓ 7) Cmax: ↓ 7% (↓ 13 til ↓ 0) Cmin: IB
English: Cmax: ↓ 23% (↓ 30 to ↑ 16) Efavirenz:
Danish: Cmax: ↓ 23% (↓ 30 til ↑ 16)
English: Renal management in HIV-1 infected patients
Danish: HCV-inficerede patienter.
English: Separate preparations of emtricitabine and tenofovir disoproxil are available for treatment of HIV-1 infection if it becomes necessary to discontinue or modify the dose of one of the components of
Danish: infektion, hvis det bliver nødvendigt at seponere eller ændre dosen af ét af Emtricitabine/Tenofovirdisoproxil Krkas indholdsstoffer.
English: HDPE bottle
Danish: HDPE tabletbeholderen
English: While taking Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV:
Danish: Hvis De tager Emtricitabine/Tenofovir disoproxil Krka for at reducere risikoen for at få HIV:
English: expected to decrease plasma concentrations of velpatasvir.
Danish: Samtidig administration af sofosbuvir/velpatasvir og efavirenz forventes at reducere plasmakoncentrationen af velpatasvir.
English: Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly (see section 4.4).
Danish: Lamivudin og Emtricitabine/Tenofovir disoproxil Krka må ikke administreres samtidigt (se pkt.
English: + Emtricitabine/Rilpivirine/ Tenofovir disoproxil (200 mg/25 mg/245 mg q.d.)
Danish: + Emtricitabin/Rilpivirin/ Tenofovirdisoproxil (200 mg/25 mg/245 mg q.d.)
English: Emtricitabine/Tenofovir disoproxil (200 mg/245 mg q.d.)
Danish: Emtricitabin/Tenofovirdisoproxil (200 mg/245 mg q.d.)
English: Increased plasma concentrations of tenofovir resulting from co administration of tenofovir disoproxil, sofosbuvir/velpatasvir/voxilaprevir and darunavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Danish: Øget plasmakoncentration af tenofovir som følge af samtidig administration af tenofovirdisoproxil, sofosbuvir/velpatasvir/voxila previr og darunavir/ritonavir kan øge risikoen for bivirkninger relateret til tenofovirdisoproxil, herunder nyrerelaterede bivirkninger.
English: Psychiatric disorders:
Danish: For tabletbeholderen:
English: Increased plasma concentrations of tenofovir resulting from coadministration of tenofovir disoproxil, ledipasvir/sofosbuvir and atazanavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Danish: Øget plasmakoncentration af tenofovir som følge af samtidig administration af tenofovirdisoproxil, ledipasvir/sofosbuvir og atazanavir/ritonavir kan øge risikoen for bivirkninger relaterede til tenofovirdisoproxil, herunder nyrerelaterede bivirkninger.
English: Cmax:↔ Cmin: N/A
Danish: Cmax: ↔ Cmin: ↔